# A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

> **NCT03301883** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 62 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** NSAIDs
- **DRUG:** CSs
- **DRUG:** MTX

## Key facts

- **NCT ID:** NCT03301883
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2021-09-04
- **Final completion:** 2022-08-05
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301883, "A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03301883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*